Pabiručių sveikata - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 9,170 | 16,520 | 12,270 | 32,265 | 35,372 | 32,010 | 42,230 | 41,392 |
| Profit before tax | - | - | - | - | - | - | 2,986 | 796 |
| Net profit | -231 | 3,636 | 1,781 | 5,424 | 732 | -1,189 | 2,831 | 743 |
| Equity | 2,446 | 6,081 | 7,862 | 13,286 | 12,606 | 11,417 | 14,247 | 14,990 |
| Liabilities | 90 | 814 | 260 | 533 | 431 | 862 | 676 | 458 |
| Non-current assets | 0 | 0 | 0 | 0 | 1,742 | 906 | 70 | 1 |
| Current assets | 2,536 | 6,760 | 8,042 | 13,819 | 11,295 | 11,373 | 14,853 | 15,447 |
| Total assets | 2,536 | 6,760 | 8,042 | 13,819 | 13,037 | 12,279 | 14,923 | 15,448 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 4,060 | 4,662 | 4,497 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +122.0% | +80.2% | -25.7% | +163.0% | +9.6% | -9.5% | +31.9% | -2.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -9.1% | 53.8% | 22.1% | 39.3% | 5.6% | -9.7% | 19.0% | 4.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -9.4% | 59.8% | 22.7% | 40.8% | 5.8% | -10.4% | 19.9% | 5.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -2.5% | 22.0% | 14.5% | 16.8% | 2.1% | -3.7% | 6.7% | 1.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | 7.1% | 1.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 4,585 | 8,260 | 6,135 | 16,133 | 17,686 | 16,005 | 21,115 | 20,696 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Pabiručių sveikata - Social security debts
The company had no debts to Sodra
Pabiručių sveikata - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Pabiručių sveikata is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-08-28 | 2026-09-02 | 0.16 |
| 2026-08-02 | 2026-08-20 | 0.16 |
| 2026-06-28 | 2026-07-26 | 0.15 |
| 2026-05-28 | 2026-06-05 | 0.15 |
| 2026-04-30 | 2026-05-25 | 0.15 |
| 2026-03-29 | 2026-04-28 | 0.15 |
| 2026-03-02 | 2026-03-27 | 0.15 |
| 2026-01-29 | 2026-03-01 | 0.12 |
| 2026-01-15 | 2026-01-24 | 0.12 |
| 2026-01-01 | 2026-01-14 | 0.08 |
| 2025-11-28 | 2025-12-29 | 0.08 |
| 2025-09-28 | 2025-11-25 | 0.08 |
| 2025-09-19 | 2025-09-23 | 0.08 |
| 2025-06-28 | 2025-07-21 | 0.08 |
| 2025-06-19 | 2025-06-24 | 0.08 |
| 2025-05-29 | 2025-06-05 | 0.08 |
| 2025-04-28 | 2025-05-24 | 0.08 |
| 2025-01-16 | 2025-02-10 | 0.04 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Pabiruciu sveikata, UAB (code 304177047) is a Private Limited Liability Company operating in medical specialists activities. In 2025, the company generated revenue of €41.4K, slightly below the 2024 level of €42.2K, indicating a 2.0% year-on-year decline after strong growth in the prior year. Revenue increased from €32.0K in 2023 to €42.2K in 2024, then remained broadly stable in 2025. Net profit improved from a loss of €1.2K in 2023 to a profit of €2.8K in 2024, and then moderated to €743 in 2025, with a profit margin of 1.8%. The balance sheet remained solid, with total assets rising from €12.3K in 2023 to €15.4K in 2025, while equity increased to €15.0K and liabilities declined to €458. The equity ratio was 97.0%, and debt-to-equity was 0.03, showing very low leverage. Return on equity was 5.0% and return on assets 4.8% in 2025. Asset turnover reached 2.68x, and revenue per employee was €20.7K, with profit per employee of €372.